ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

Interview: “People don’t understand Clinical Trials.

September 5, 1997

ACCC Annual Meeting Jan. 27-29; Upton To speak

November 4, 1977

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

July 11, 2014

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

NCI Director Harold Varmus Plans New Center For Cancer Genomics To Lead The Cancer Genome Atlas Program.

September 10, 2010

Litton’s Government Contracts Status Under Review

September 6, 1985